ArticleJACC. Case reports2026
Cyclophosphamide-Induced Hemorrhagic Myocarditis.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCyclophosphamide is a widely used chemotherapeutic agent with a spectrum of toxicities, including a rare drug-related hemorrhagic myocarditis. CASE SUMMARY: A 63 -year-old male with myelofibrosis underwent haploidentical stem cell transplantation with 95 mg/kg cyclophosphamide conditioning. He developed tachycardia, lower-extremity edema, and pulmonary congestion 8 days later. Troponin-T was 512 ng/L, and N-terminal pro-brain natriuretic peptide was 20,142 pg/mL, each previously normal. Electrocardiogram showed low-voltage QRS complexes in limb leads. Echocardiography demonstrated significant left ventricular wall thickening (17 mm), preserved left ventricular ejection fraction (54%), and decreased global longitudinal strain (-9%), all previously normal. Cardiac magnetic resonance imaging suggested myocardial edema and inflammation. Left ventricular T2∗ value near 20 ms suggested intramyocardial hemorrhage. Volume overload and supraventricular arrhythmias were managed conservatively. DISCUSSION: To our knowledge, there are no reported cases of nonfatal cyclophosphamide-induced hemorrhagic myocarditis at a dose <100 mg/kg. TAKE-HOME MESSAGE: An expedited multimodal cardiac imaging approach is warranted when this rare cardiotoxicity is suspected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.